Home・Aandelen Lijst・Vir Biotechnology Inc

Vir Biotechnology Inc

Open

SectorGezondheidszorg

8.62 -2.05

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

8.58

Max

8.93

Belangrijke statistieken
By Trading Economics
Inkomsten	-83M -126M
Verkoop	-64M -29K
EPS	-0.85
Winstmarge	433,431.034
Werknemers	367
EBITDA	-83M -123M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+142.15% upside

Dividenden
By Acuity
Volgende Winsten	5 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-176M 1.5B
Vorige openingsprijs	10.67
Vorige sluitingsprijs	8.62

Nieuwssentiment

By Acuity

67%

33%

285 / 340 Rangschikking in Healthcare

Vir Biotechnology Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

28 jul 2026, 15:46 UTC

Correlated Moves

Shares lower today, pressured by declines in biotech sector.

27 jul 2026, 20:07 UTC

Vir Biotechnology's shares are higher today, continuing gains since Friday. The broader market is influenced by declining oil prices and lower Treasury yields.

25 jul 2026, 00:01 UTC

Vir Biotechnology Inc shares are higher in after-market trading, recovering from earlier lows. The stock is near the lower end of its one-month trading range.

24 jul 2026, 23:31 UTC

Vir Biotechnology Inc shares are higher in after-market trading, reflecting notable gains since Friday's close, despite no specific news driving the price action.

21 jul 2026, 17:16 UTC

Correlated Moves

Vir Biotechnology Inc's shares are higher today, supported by a positive trend in the broader biotech sector. Earlier, shares pulled back but have since recovered.

20 jul 2026, 21:02 UTC

Vir Biotechnology Inc shares fell during after-market hours amid broader market declines following a reported drop in the Leading Economic Index for June.

Peer Vergelijking

Prijswijziging

Vir Biotechnology Inc Prognose

Koersdoel

By TipRanks

142.15% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 21.43 USD 142.15%

Hoogste 30 USD

Laagste 16 USD

Gebaseerd op 9 Wall Street-analisten die 12-maands prijsdoelen bieden voor Vir Biotechnology Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

9 ratings

Buy

Hold

Sell

Gebaseerd op 9 analisten die aandelenratings hebben gegeven aan Vir Biotechnology Inc - Dist in de afgelopen 3 maanden.

Sentiment

By Acuity

285 / 340 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Vir Biotechnology Inc

Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.